| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1055/S-2001-16891 |
| P698 | PubMed publication ID | 11547361 |
| P2093 | author name string | Boedeker BG | |
| P433 | issue | 4 | |
| P304 | page(s) | 385-394 | |
| P577 | publication date | 2001-08-01 | |
| P1433 | published in | Seminars in Thrombosis and Hemostasis | Q15751825 |
| P1476 | title | Production processes of licensed recombinant factor VIII preparations | |
| P478 | volume | 27 |
| Q45874428 | A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose |
| Q39198341 | Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. |
| Q90260894 | BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review |
| Q38725317 | BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics |
| Q38731189 | Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience |
| Q38726126 | Bioreactor productivity and media cost comparison for different intensified cell culture processes |
| Q41639731 | Effect of transmembrane pressure on Factor VIII yield in ATF perfusion culture for the production of recombinant human Factor VIII co-expressed with von Willebrand factor |
| Q39811881 | Enhanced Proteolytic Processing of Recombinant Human Coagulation Factor VIII B-Domain Variants by Recombinant Furins. |
| Q37625927 | Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer |
| Q30397756 | Expression and characterization of a codon-optimized blood coagulation factor VIII. |
| Q35810108 | Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings |
| Q36810282 | Haemophilia therapies |
| Q34499850 | In vitro and In vivo Model Systems for Hemophilia A Gene Therapy |
| Q38534584 | Industrial production of clotting factors: Challenges of expression, and choice of host cells |
| Q38722283 | Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor |
| Q47288278 | Isotope labeling to determine the dynamics of metabolic response in CHO cell perfusion bioreactors using MALDI-TOF-MS. |
| Q24630417 | Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies |
| Q43105104 | Lectin binding assays for in-process monitoring of sialylation in protein production |
| Q34556878 | Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII |
| Q50490090 | Mixture of three amino acids as stabilizers replacing albumin in lyophilization of new third generation recombinant factor VIII GreenGene F. |
| Q37891089 | Pharmacotherapy of haemophilia A. |
| Q30881997 | Purification and characterization of a new recombinant factor VIII (N8). |
| Q39977061 | Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity |
| Q37139733 | Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A. |
| Q36236913 | The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics |
| Q35779195 | Treating haemophilia A with recombinant blood factors: a comparison |
Search more.